These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 18393850)

  • 21. Antituberculosis drugs in children.
    Schaaf HS; Garcia-Prats AJ; Donald PR
    Clin Pharmacol Ther; 2015 Sep; 98(3):252-65. PubMed ID: 26095192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extensively and pre-extensively drug resistant tuberculosis in clinical isolates of multi-drug resistant tuberculosis using classical second line drugs (levofloxacin and amikacin).
    Mirza IA; Khan FA; Khan KA; Satti L; Ghafoor T; Fayyaz M
    J Coll Physicians Surg Pak; 2015 May; 25(5):337-41. PubMed ID: 26008658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tuberculosis clinical trial update and the current anti-tuberculosis drug portfolio.
    Palomino JC; Martin A
    Curr Med Chem; 2013; 20(30):3785-96. PubMed ID: 23862617
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical comprehensive physicochemical and pharmacokinetic profiling of novel nitroimidazole derivative IIIM-019 - A potential oral treatment for tuberculosis.
    Kour G; Kumar A; Singh PP; Sharma S; Bhagat A; Vishwakarma RA; Ahmed Z
    Pulm Pharmacol Ther; 2016 Oct; 40():44-51. PubMed ID: 27457685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive physicochemical, pharmacokinetic and activity profiling of anti-TB agents.
    Lakshminarayana SB; Huat TB; Ho PC; Manjunatha UH; Dartois V; Dick T; Rao SP
    J Antimicrob Chemother; 2015 Mar; 70(3):857-67. PubMed ID: 25587994
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacologic considerations in use and development of antituberculosis drugs.
    Davies G
    Cold Spring Harb Perspect Med; 2014 Sep; 5(1):a021170. PubMed ID: 25237145
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emergence and treatment of multidrug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis in South Africa.
    Streicher EM; Müller B; Chihota V; Mlambo C; Tait M; Pillay M; Trollip A; Hoek KG; Sirgel FA; Gey van Pittius NC; van Helden PD; Victor TC; Warren RM
    Infect Genet Evol; 2012 Jun; 12(4):686-94. PubMed ID: 21839855
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.
    Poce G; Cocozza M; Consalvi S; Biava M
    Eur J Med Chem; 2014 Oct; 86():335-51. PubMed ID: 25173852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current status and future trends in the diagnosis and treatment of drug-susceptible and multidrug-resistant tuberculosis.
    Ahmad S; Mokaddas E
    J Infect Public Health; 2014; 7(2):75-91. PubMed ID: 24216518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs.
    Davies GR; Nuermberger EL
    Tuberculosis (Edinb); 2008 Aug; 88 Suppl 1():S65-74. PubMed ID: 18762154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019.
    Pranger AD; van der Werf TS; Kosterink JGW; Alffenaar JWC
    Drugs; 2019 Feb; 79(2):161-171. PubMed ID: 30617959
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and operational value of the extensively drug-resistant tuberculosis definition.
    Migliori GB; Besozzi G; Girardi E; Kliiman K; Lange C; Toungoussova OS; Ferrara G; Cirillo DM; Gori A; Matteelli A; Spanevello A; Codecasa LR; Raviglione MC;
    Eur Respir J; 2007 Oct; 30(4):623-6. PubMed ID: 17690121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of New Tuberculosis Drugs: Translation to Regimen Composition for Drug-Sensitive and Multidrug-Resistant Tuberculosis.
    Ernest JP; Strydom N; Wang Q; Zhang N; Nuermberger E; Dartois V; Savic RM
    Annu Rev Pharmacol Toxicol; 2021 Jan; 61():495-516. PubMed ID: 32806997
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trends in the discovery of new drugs for Mycobacterium tuberculosis therapy with a glance at resistance.
    Lohrasbi V; Talebi M; Bialvaei AZ; Fattorini L; Drancourt M; Heidary M; Darban-Sarokhalil D
    Tuberculosis (Edinb); 2018 Mar; 109():17-27. PubMed ID: 29559117
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New structural classes of antituberculosis agents.
    Kumar V; Patel S; Jain R
    Med Res Rev; 2018 Mar; 38(2):684-740. PubMed ID: 28598559
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents.
    Pieroni M; Wan B; Cho S; Franzblau SG; Costantino G
    Eur J Med Chem; 2014 Jan; 72():26-34. PubMed ID: 24333612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current status of some antituberculosis drugs and the development of new antituberculous agents with special reference to their in vitro and in vivo antimicrobial activities.
    Tomioka H
    Curr Pharm Des; 2006; 12(31):4047-70. PubMed ID: 17100611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence and molecular characteristics of drug-resistant Mycobacterium tuberculosis in Beijing, China: 2006 versus 2012.
    Yin QQ; Jiao WW; Li QJ; Xu F; Li JQ; Sun L; Li YJ; Huang HR; Shen AD
    BMC Microbiol; 2016 May; 16():85. PubMed ID: 27176471
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthetic investigational new drugs for the treatment of tuberculosis.
    Kwon YS; Koh WJ
    Expert Opin Investig Drugs; 2016; 25(2):183-93. PubMed ID: 26576631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.